1	Maternal smoking DNA methylation risk score associated with health
2	outcomes in offspring of European and South Asian ancestry
3	
4	Wei Q. Deng ^{1,2,3*} , Nathan Cawte ⁴ , Natalie Campbell ³ , Sandi M. Azab ^{3,5} , Russell J de Souza ^{3,5} ,
5	Amel Lamri ^{3,4} , Katherine M. Morrison ⁶ , Stephanie A. Atkinson ⁶ , Padmaja Subbarao ⁷ , Stuart E.
6	Turvey ⁸ , Theo J. Moraes ^{7,9} , Koon K. Teo ^{3,4,5} , Piush Mandhane ¹⁰ , Meghan B. Azad ¹¹ , Elinor
7	Simons ¹² , Guillaume Pare ^{4,5,13,14} , Sonia S. Anand ^{3,4,5*}
8	
9	
10	1. Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton, Hamilton,
11	Canada.
12	2. Department of Psychiatry and Behavioural Neurosciences, McMaster University,
13	Hamilton, Canada.
14	3. Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton,
15	Canada.
16	4. Population Health Research Institute, David Braley Cardiac, Vascular and Stroke
17	Research Institute, Hamilton, Canada.
18	5. Department of Health Research Methods, Evidence, and Impact, McMaster University,
19	Hamilton, Canada.
20	6. Department of Pediatrics, McMaster University, Hamilton, Canada.
21	7. Department of Pediatrics, University of Toronto, Toronto, Canada.
22	8. Department of Pediatrics, BC Children's Hospital, The University of British Columbia,
23	Vancouver, Canada

24	9. Program in Translational Medicine, SickKids Research Institute, Toronto, Canada
25	10. Department of Pediatrics, University of Alberta, Edmonton, Canada
26	11. Children's Hospital Research Institute of Manitoba, Department of Pediatrics and Child
27	Health, University of Manitoba, Winnipeg, Canada
28	12. Section of Allergy and Immunology, Department of Pediatrics and Child Health,
29	University of Manitoba, Canada
30	13. Thrombosis and Atherosclerosis Research Institute, David Braley Cardiac, Vascular and
31	Stroke Research Institute, Hamilton, Canada
32	14. Department of Pathology and Molecular Medicine, McMaster University, Michael G.
33	DeGroote School of Medicine, Hamilton, Canada
34	
35	*Correspondence: <u>dengwq@mcmaster.ca</u> ; <u>anands@mcmaster.ca</u>
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	

46 Abstract

47 Maternal smoking has been linked to adverse health outcomes in newborns but the extent to 48 which it impacts newborn health has not been quantified through an aggregated cord blood DNA 49 methylation (DNAm) score. Here we examine the feasibility of using cord blood DNAm scores 50 leveraging large external studies as discovery samples to capture the epigenetic signature of 51 maternal smoking and its influence on newborns in White European and South Asian 52 populations. We first examined association between individual CpGs and cigarette smoking 53 during pregnancy, smoking exposure in two White European birth cohorts (n = 744). Several 54 previously reported genes for maternal smoking were supported, with the strongest and most consistent signal from the *GFI1* gene (6 CpGs with $p < 5 \times 10^{-5}$). Leveraging established CpGs for 55 56 maternal smoking, we constructed a cord blood epigenetic score of maternal smoking that was 57 internally validated in one of the European-origin cohorts (n = 347). This score was then tested 58 for association with smoking status, secondary smoking exposure during pregnancy, and health 59 outcomes in offspring measured after birth in an independent white European (n = 397) and a 60 South Asian birth cohort (n = 504). The epigenetic maternal smoking score was strongly associated with smoking status during pregnancy (OR=1.09 [1.07,1.10], $p=1.96\times10^{-32}$) and more 61 hours of self-reported smoking exposure per week (1.97 [1.22, 2.71], $p=2.80\times10^{-7}$) in White 62 63 Europeans, but not with self-reported exposure (p > 0.05) in South Asians. The same score was consistently associated with smaller birth size (-0.22 cm [-0.35, -0.083], p=0.0016) and lower 64 birth weight (-0.05kg [-0.075, -0.025], $p = 3.42 \times 10^{-4}$) in the combined South Asian and White 65 66 European cohorts. This cord blood epigenetic score can help identify babies exposed to maternal 67 smoking and assess its long-term impact on growth. Notably, these results indicate a consistent 68 association between the DNAm signature of maternal smoking and a small body size and low

birthweight in newborns, in both white European mothers who exhibited some amount ofsmoking and in South Asian mothers who themselves were not active smokers.

71

72 Introduction

Maternal smoking has adverse effects on offspring health including pre-term delivery (1.2). 73 74 stillbirth (3), and low birth weight (4), and is associated with pregnancy complications such as 75 maternal higher blood pressure, and gestational diabetes (5). Consistent with the Developmental 76 Origins of Health and Disease (DOHaD) hypothesis, maternal smoking exposes the developing 77 fetus to harmful chemicals in tobacco that negatively impact the health of newborns, resulting in 78 early-onset metabolic diseases, such as childhood obesity (6–9). Yet self-reported smoking status 79 is subject to underreporting among pregnant women (10-12). This could subsequently impact the 80 effectiveness of interventions aimed at reducing smoking during pregnancy and may skew data 81 on the risks associated with maternal smoking.

82

83 DNA methylation is one of the most commonly studied epigenetic mechanisms by which 84 cells regulate gene expression, and is increasingly recognized for its potential as a biomarker 85 (13). Differential DNA methylation has been established as a reliable biochemical response to 86 cigarette smoking and was shown to capture the long-lasting effects of persistent smoking in ex-87 smokers (14–16). Recent large epigenome-wide association studies (EWAS) have robustly 88 identified differentially methylated cytosine-phosphate-guanine (CpG) sites associated with 89 adult smoking (15,17,18) and maternal smoking (19,20). Our recent systematic review of 17 cord 90 blood epigenome-wide association studies (EWAS) found that out of the 290 CpG sites reported 91 to be associated with at least one of the following: maternal diabetes, pre-pregnancy body mass

92 index (BMI), diet during pregnancy, smoking, and gestational age, 19 sites were identified in 93 more than one study and all of them associated with maternal smoking (21). Furthermore, these 94 findings have led to a more thorough investigation of the epigenetic mechanisms underlying 95 associations between well-established epidemiological exposures and outcomes, such as the 96 relationship between maternal smoking and birth weight in Europeans (20,22–25) and the less 97 studied African American populations (24) as well as between maternal diet and cardiovascular 98 health (26).

99

100 Only a handful of cohort studies were designed to assess the influence of maternal 101 exposures on DNA methylation changes in non-Europeans (24,27). It has been suggested that 102 systematic patterns of methylation (28), such as cell composition, could differ between 103 individuals of different ancestral backgrounds, which could in turn confound the association 104 between differential DNAm and smoking behaviours (29). These systematic differences also 105 contribute to different smoking-related methylation signals at individual CpGs (30). Thus, a 106 comparative study of maternal smoking exposure is a first step towards generalizing existing EWAS results to other populations and a necessary step towards addressing health disparities 107 108 that exist between populations due to societal privilege, including race or ethnicity and 109 socioeconomic factors.

110

A promising direction in epigenetic studies of adult smoking is the application of a methylation score (31); this strategy can also be applied to disseminate current knowledge on differential DNA methylation studies of maternal smoking. A methylation score is usually tissuespecific and combines information from multiple CpGs using statistical models (13). Reducing

the number of predictors and measurement noise in the data can lead to better statistical power and a more parsimonious instrument for subsequent analyses. It is also of interest to determine whether methylation scores demonstrate the capacity to predict outcomes in diverse human populations, given the presence of systematic differences in methylation patterns due to ancestral backgrounds (28).

120

121 In this paper, we investigated the epigenetic signature of maternal smoking on cord blood 122 DNA methylation in newborns, as well as its association with newborn and later life outcomes in 123 one South Asian which refers to people who originate from the Indian subcontinent, and two 124 predominantly European-origin birth cohorts. Similar to the Born in Bradford study (32), we 125 observed several differentiating epidemiological characteristics between South Asian and European-origin mothers. Notably, almost none of the South Asian mothers were current 126 127 smokers and had low smoking rates pre-pregnancy as compared to European mothers, which is 128 consistent with the broader trends of lower smoking rates in South Asian females (33). Another 129 relevant observation is the small birth size and low birth weight in the South Asian newborns. 130 These differences in newborn size and weight may be influenced by various factors, including 131 maternal nutrition, genetics, and socioeconomic status. Keeping these differences in mind, we 132 first conducted cohort-specific epigenetic association studies between available CpGs and 133 maternal smoking in the predominantly European-origin cohorts, benchmarking with previously 134 identified CpGs for maternal smoking and adult smoking. Second, we leveraged the reported 135 summary statistics from existing large EWASs to construct a methylation risk score (MRS) for 136 maternal smoking. The MRS was first internally validated in one of the European-origin cohorts 137 and then tested in a second independent European-origin cohort. Third, we examined the

association between maternal smoking MRS and newborn health outcomes, including length,
weight, BMI ponderal index, and early-life anthropometrics in both European and South Asian
cohorts.

141

142

143 Materials and Methods

144

145 **Study population**

146 The NutriGen Alliance is a consortium consisting of four prospective, population-based birth 147 cohorts that enrolled birthing mother and newborn pairs in Canada. Details of these cohorts have 148 been described elsewhere (34). The current investigation focused on i). European-origin 149 offspring from the population-based CHILD study who were selected for methylation analysis, 150 ii). The Family Atherosclerosis Monitoring In early life (FAMILY) study that is predominately 151 European-origin, and iii). The SouTh Asian biRth cohorT (START) study that is exclusively 152 comprised of people who originated from the Indian subcontinent known as South Asians. The 153 ethnicity of the parents was self-reported and recorded at baseline in all three cohorts. Biological 154 samples, clinical assessments, and questionnaires were used to derive health phenotypes and an 155 array of genetic, epigenetic, and metabolomic data. The superordinate goal of the NutriGen study 156 is to understand how nutrition, environmental exposures, and physical health of mothers impact 157 the health and early development of their offspring using a multi-omics approach.

158

159 Methylation data processing and quality controls

160 Newborn cord blood samples were processed using two methylation array technologies. About 161 half of the START samples and selected samples from CHILD were hybridized to the Illumina 162 Human-Methylation450K BeadChip (HM450K) array, which covers CpGs in the entire genome 163 (35) The raw methylation data were generated by the Illumina iScan software and separately pre-164 processed for START and CHILD using the "sesame" R package following pipelines designed 165 for HM450K BeadChip (36). The FAMILY samples were profiled using a targeted array based 166 on the Infinium Methylation EPIC designed by the Genetic and Molecular Epidemiology 167 Laboratory (GMEL; Hamilton, Canada). The GMEL customized array includes ~3000 CpG sites 168 that were previously reported to associate with complex traits or exposures and was designed to 169 maximize discovery while keeping the costs of profiling epigenome-wide DNA methylation 170 down. The targeted methylation data were pre-processed using a customized quality control 171 pipeline and functions from the "sesame" R package recommended for EPIC.

172

173 Pre-processed data were then used to derive the β -value matrix, where each column gives 174 the methylation level at a CpG site as a ratio of the probe intensity to the overall probe intensity. 175 Additional quality control filters were applied to the final beta-value matrices to remove samples 176 with > 10% missing probes and CpG probes with > 10% samples missing. Cross-reactive probes 177 and SNP probes were removed as recommended for HM450 (37) and EPIC arrays (38,39). For 178 CpG probes with a missing rate <10%, mean imputation was used to fill in the missing values. 179 We further excluded samples that were either mismatches between reported sex and methylation-180 inferred sex or were duplicates. Finally, considering the low prevalence of smokers, we sought to 181 reduce spurious associations by removing non-informative probes that were either all 182 hypomethylated (β -value < 0.1) or hypermethylated (β -value > 0.9), which have been shown to

have less optimal performance (40). A summary of the sample and probe inclusion/exclusion is
shown in Supplementary Table 1. A detailed description of pre-processing and quality control
steps is included in Supplementary Material.

186

187 Cell-type proportions (CD8T, CD4T, Natural Killer cells, B cells, monocytes, granulocytes, and nucleated red blood cells) were estimated following a reference-based 188 189 approach developed blood (41) R for cord and using packages 190 "FlowSorted.CordBloodCombined.450k" and "FlowSorted.Blood.EPIC". All data processing 191 and subsequent analyses were conducted in R v.4.1.0 (42).

192

193 Phenotype data processing and quality controls

194 At the time of enrollment, all pregnant women completed a comprehensive questionnaire that 195 collected information on prenatal diet, smoking, education, socioeconomic factors, physical 196 activities and health as detailed previously (43,44). Maternal smoking history (0=never smoked, 197 1=quit before this pregnancy, 2=quit during this pregnancy, or 3=current smoker) was assessed 198 during the second trimester (at baseline). Smoke exposure was measured as "number of hours 199 exposed per week". GDM was determined based on a combination of oral glucose tolerance test 200 (OGTT), self-report, and reported diabetic treatments (insulin, pills, or restricted diet). For South 201 Asian mothers in START, the same OGTT threshold as Born in Bradford (27,32) was used, 202 while the International Association of the Diabetes and Pregnancy Study Groups (IASDPSG) 203 criteria (45) for OGTT were used in CHILD and FAMILY cohorts. Mode of delivery 204 (emergency c-section vs. other) was collected at the time of delivery.

206 Newborn length and weight were collected immediately after birth and extracted from 207 medical chart. The newborns were then followed up at 1, 2, 3, and 5 years of age and provided 208 basic anthropometric measurements, including height, weight, hip and waist circumference, BMI, 209 sum of the skinfolds (triceps skinfold and subscapular skinfold). Additional phenotypes included 210 smoking exposures (hours per week) at home, potential allergy based on mother reporting any of: 211 eczema, hay fever, wheeze, asthma, food allergy (egg, cow milk, soy, other) for her child in 212 FAMILY and START, and asthma based on mother's opinion in CHILD ("In your opinion, does 213 the child have any of the following? Asthma").

214

215 Phenotype and Methylation Data Consolidation

216 The current investigation examines the impact of maternal smoking or smoke exposure on DNA 217 methylation derived from newborn cord blood in START and the two predominately European 218 cohorts (CHILD and FAMILY). To maximize sample size in FAMILY and CHILD, we retained 219 either self-identified or genetically confirmed Europeans based on available genetic data 220 (Supplementary Table 1). The cohorts consist of representative population samples without 221 enrichment for any clinical conditions, though only singleton mothers were invited to participate. 222 For continuous phenotypes, an analysis of variance (ANOVA) using the F-statistics or a two-223 sample *t*-test was used to compare the mean difference across the three cohorts or two groups, 224 respectively. For categorical phenotypes, a chi-square test of independence was used to compare 225 the difference in frequencies of observed categories. Note that three of the categories under 226 smoking history in the START cohort had expected cell counts less than 5, and was thus 227 excluded from the comparison, the reported *p*-value was for CHILD and FAMILY.

228

The final analytical datasets, after combining the quality-controlled methylation data and phenotypic data, included 352, 411, and 504 mother-newborn pairs from CHILD, FAMILY, and START, respectively. Demographic characteristics and relevant covariates of the epigenetic subsample and the overall sample are summarized in Table 1 and Supplementary Table 2, respectively.

234

235 Epigenome-Wide Association of Maternal Smoking in European Cohorts

236

237 Since there were no current smokers in START (Table 1), we tested the association between 238 maternal smoking and differential methylated sites in FAMILY (# of CpG = 2,544) and CHILD 239 (# of CpG = 200,050). The primary outcome variable was "current smoker", defined by mothers 240 self-identified as currently smoking during the pregnancy vs. those who never smoked or quit 241 either before or during pregnancy. We also included a secondary outcome variable "ever 242 smoker", defined by mothers who are current smokers or have quit smoking vs. those who never 243 smoked. A tertiary outcome was smoking exposure, measured by the number of hours per week 244 reported by the expectant mothers, and was available in all cohorts. We summarized the type of 245 analyses for different outcomes in Supplementary Table 3.

246

We first conducted a separate epigenetic association study in each cohort, testing the association between methylation β -values at individual CpGs and the smoking phenotype using either a logistic regression model for smoking status or a linear regression for smoking exposure as the outcome. The model adjusted for additional covariates including the estimated cord blood cell proportions, maternal age, social disadvantage index, which is a continuous composite

measure of social and economic exposures (46), mother's years of education, GDM, and parity.
The smoking exposure variable was skewed, and a rank-based transformation was applied to
mimic a standard normal distribution.

255

256 We then meta-analyzed association results for maternal smoking status in the European cohorts using an inverse variance-weighted fixed-effect model. The meta-analysis was conducted 257 258 for 2,112 CpGs that were available in both CHILD (profiled using HM450K) and FAMILY 259 (profiled using the targeted array). For the tertiary outcome, we conducted an inverse variance 260 meta-analysis including START using both a fixed-effect model. For each EWAS or meta-261 analysis, the false discovery rate (FDR) adjustment was used to control multiple testing and we 262 considered CpGs that passed an FDR-adjusted p-value < 0.05 to be relevant for maternal 263 smoking.

264

265 Using DNA Methylation to Construct Predictive Models for Maternal Smoking

266

267 We sought to construct a predictive model in the form of a methylation risk score (MRS) using reported associations of maternal smoking. The proposed solution adapted the existing lassosum 268 269 method (47) that was originally designed for polygenic risk scores, where the matrix of SNP 270 genotypes (X) can be conveniently replaced by the β -value matrix. For more details, see the 271 Supplementary Material. Briefly, an objective function under elastic-net constraint was 272 minimized to obtain the elastic-net solution γ , where only summary statistics (b) and a scalar of 273 the covariance between the β -values of the CpGs (X'X) are needed. The tuning parameters λ_1 and λ_2 were chosen by validating on the observed smoking history (as a continuous outcome) in 274

275 CHILD that produced the most significant model. The optimized λ_1 and λ_2 were then used to 276 create a final model that entails a list of CpGs and their corresponding weights, which were then 277 used to calculate a MRS for maternal smoking in the FAMILY and START samples.

278

279 The summary statistics of the discovery EWAS were obtained from EWAS catalog 280 (http://www.ewascatalog.org/) reported under "PubMed ID 27040690" by Joubert and 281 colleagues (19). The summary statistics were restricted to the analysis "sustained maternal 282 smoking in pregnancy effect on newborns adjusted for cell composition". Of the 2620 maternal 283 smoking CpGs that passed the initial screening, 2,107 were available in CHILD but only 128 284 were common to CHILD, FAMILY, and START. To evaluate whether the targeted GMEL-EPIC 285 array design has comparable performance as the epigenome-wide array to evaluate the epigenetic 286 signature of maternal smoking, a total of three MRSs were constructed, two using the 128 CpGs 287 available in all cohorts – across the HM450K and targeted GMEL-EPIC arrays – and with either 288 CHILD (n = 347 with non-missing smoking history) or FAMILY (n = 397 with non-missing 289 smoking history) as the validation cohort, and another using 2,107 CpGs that were only available 290 in CHILD and START samples with CHILD as the validation cohort. The validation model 291 considered the continuous smoking history without modification as the outcome, while 292 accounting for covariates, which included the estimated cord blood cell proportions, maternal 293 age, social disadvantage index, mother's years of education, GDM, and parity. Henceforth, we 294 referred to these derived maternal smoking scores as the FAMILY targeted MRS, CHILD 295 targeted MRS, and the HM450K MRS, respectively. To benchmark and compare with existing 296 maternal smoking MRSs, we calculated the Reese score using 28 CpGs (48,49), Richmond 297 score using 568 CpGs (49), Rauschert score using 204 CpGs (50), Joubert score using all 2,620

298 CpGs with evidence of association for maternal smoking (19), and finally a three-CpG score for 299 air pollution (51). The details of these scores and score weight can be found in Supplementary 300 Table 4.

301

302 Statistical analysis

303 For each cohort, we contrasted the three versions of the derived scores using an analysis of 304 variance analysis (ANOVA) along with pairwise comparisons using a two-sample *t*-test to 305 examine how much information might be lost due to the exclusion of more than 10-fold CpGs at 306 the validation stage, in all samples and in non-smokers. We also examined the correlation 307 structure between all derived and external MRSs using a heatmap summarizing their pairwise 308 Pearson's correlation coefficient. Then, we compared the mean difference of each MRS score 309 among smoking history using an ANOVA F-test and two-sample t-test to understand whether 310 there was a dosage dependence in the cord blood DNAm signature of maternal smoking. 311 Additionally, each score was tested against a binary outcome for current smoker vs. not, and two 312 continuous measures for smoking history and weekly smoking exposure. The binary outcome 313 was tested using a logistic regression model and the predictive performance was assessed using 314 area under the receiver operating characteristic curve (AUC). The continuous outcome was 315 examined using a linear regression model and its performance was quantified using the adjusted \mathbf{R}^2 . 316

317

For the derived MRS, we empirically assessed whether the resulting score was portable to the START cohort by examining the distribution of the final score among the overall samples and never smokers. The comparison examined a mean difference using an analysis of variance *F*-test,

a variance difference using a Levene's test, and the overall distribution using a non-parametric
Anderson-Darling test. Finally, we tested the association between each maternal smoking MRS
and smoking phenotypes in mothers, as well as offspring phenotypes using a linear regression
model, when applicable, adjusting for the child's age at each visit. The association results were
meta-analyzed for phenotypes with homogeneous effects across the cohorts using a fixed-effect
model.

- 327
- 328

329 **Results**

330

331 Cohort Sample Characteristics

332 The analyses included 763 European mother-child pairs with cord blood DNAm data from the 333 CHILD study (CHILD; n = 352)(52) and The Family Atherosclerosis Monitoring In earLY life 334 (FAMILY; n = 411) study (43), and 503 South Asian mother-child pairs from The SouTh Asian 335 biRth cohorT (START) study (44). We observed lower past smoking and missingness on 336 smoking history among pregnant women in START as compared to CHILD or FAMILY using 337 the epigenetic subsample (Table 1) and the overall sample (Supplementary Table 2). Pregnant 338 women in START were significantly different from CHILD or FAMILY in that they were on 339 average younger at delivery, had a lower BMI, and a higher rate of GDM, in line with other 340 cohort studies in South Asian populations (53,54). As compared to START, newborn infants 341 from CHILD and FAMILY had a longer gestational period, a higher birth weight, and a higher 342 BMI at birth (Table 1; Supplementary Table 2). We observed no difference between cohorts in 343 terms of parity or newborn sex in the epigenetic subsample (Table 1).

344

345 Within the European epigenetic subsample, of the 744 mother-newborn pairs with 346 complete smoking history data, 40 (5.3%) newborns were exposed to current maternal smoking, 347 which is on the lower end of the spectrum for the prevalence of smoking during pregnancy 348 (9.2%-32.5%) among Canadians (55). In addition, mothers who smoked during pregnancy were 349 on average younger, had fewer years of education, and had higher household exposure to 350 smoking (Supplementary Table 6). However, there was no statistically significant difference 351 between newborns exposed to current and none or previous smoking in terms of birth weight, 352 birth length, gestational age, or estimated cord blood cell proportions.

353

354

355 Epigenetic Association of Maternal Smoking in White Europeans

356 The two predominantly White European cohorts, FAMILY (n = 397) and CHILD (n = 347), 357 contributed to the meta-analysis of maternal smoking for both the primary outcome of current 358 smoking (Figure 2-A) and the secondary outcome of ever smoking (Supplementary Figure 1). 359 The top associated CpGs with current maternal smoking were mapped to the growth factor 360 independent 1 (GFII) gene on chromosome 1, with cg12876356 as the lead (meta-analyzed effect = -1.11±0.22; meta-analyzed $p = 2.6 \times 10^{-6}$; FDR adjusted p = 0.006; Table 2). There were 361 362 no CpGs associated with the ever-smoker status at an FDR of 0.05, though the top signal 363 (cg09935388) was also mapped to the GFII gene (Pearson's r^2 correlation with cg12876356 = 0.75 and 0.68 in CHILD and FAMILY, respectively; Supplementary Figure 1). The top 364 365 associated CpG from the meta-analysis of smoking exposure (hours per week) in the European-366 origin cohorts (Figure 2-B) was cpg01798813 on chromosome 17, which was also associated

367 with maternal smoking and was consistent in the direction of association (meta-analyzed effect = -0.18±0.04; meta-analyzed $p = 1.4 \times 10^{-5}$; FDR adjusted p = 0.04; Table 2). There was no 368 369 noticeable inflation of empirical type I error in the association p-values from the meta-analysis, 370 with the median of the observed association test statistic roughly equal to the expected median 371 (Supplementary Figure 2). As a sensitivity analysis, we repeated the analysis for the continuous 372 smoking exposure under rank transformation vs. raw phenotype for the associated CpG in GFII 373 and examined the regression diagnostics (Supplementary Material), and found that the model 374 under rank-transformation deviated less from assumptions. Further, we observed consistency in 375 the direction of association for the 128 CpGs that overlapped between our meta-analysis and the 376 2,620 CpGs with evidence of association for maternal smoking (19) (Supplementary Figure 3). 377 Specifically, the Pearson's correlation coefficient for maternal smoking and weekly smoking 378 exposure was 0.72 and 0.60, respectively. The maternal smoking and smoking exposure EWASs 379 in CHILD alone did not yield any CpGs after FDR correction (Supplementary Figure 4).

380

381

382 Methylation Risk Score (MRS) Captures Maternal Smoking and Smoking Exposure

The final MRSs, validated using CHILD European samples (n = 347), included 15 and 143 CpG markers (Supplementary Table 7) from the targeted array and the epigenome-wide HM450 array, respectively. Both produced methylation scores that were significantly associated with maternal smoking history (ANOVA F-test *p*-values = 1.0×10^{-6} and 2.4×10^{-14} in CHILD and 6.9×10^{-16} and $<2.2 \times 10^{-16}$ in FAMILY; Figure 3), and the best among alternative scores for CHILD and FAMILY (Supplementary Table 5). With the exception of the air pollution MRS, all remaining scores were marginally associated with smoking history in both CHILD and FAMILY

(Supplementary Figure 5) and correlated with each other (Supplementary Figure 6). There was no statistically significant difference in mean between the two scores in any of the three cohorts (two-sample t-test ps > 0.6) or among non-smokers (two-sample t-test ps > 0.6; Supplementary Figure 7). Since the HM450 score provides statistically more significant results in both CHILD and FAMILY with smoking history, despite the reduction in CpGs included (only 10 out of 143 CpGs present in FAMILY; Supplementary Table 5), we proceeded with the HM450 MRS model constructed using the 143 CpGs in subsequent analyses.

397

398 The HM450 MRS was significantly associated with maternal smoking history in CHILD 399 and FAMILY (n = 397), but not in START (n = 503; Figure 3) – not surprisingly – due to the 400 low number of ever-smokers (n = 2). A weak dose-dependent relationship between the MRS and 401 the four categories of maternal smoking status in the severity of exposure ([0] = never smoked;402 [1] = quit before this pregnancy; [2] = quit during this pregnancy; [3] = currently smoking) was 403 present in CHILD but was not replicated in FAMILY (Figure 3). The areas under the Receiver 404 Operating Characteristic (ROC) curve (area under the curve or AUC) for detecting current 405 smokers were 0.95 and 0.89 in CHILD and FAMILY, respectively, while the AUCs for detecting 406 ever-smokers were 0.61 and 0.60 (Supplementary Table 5), respectively. Meanwhile, the 407 maternal smoking MRS was significantly associated with increased number of hours exposed to 408 smoking per week in the two White European cohorts (1.97±0.38 hours per 1 unit of increase in 409 MRS, FDR adjusted $p = 4.2 \times 10^{-6}$; Supplementary Table 8; cohort specific p=0.0087 in CHILD and 0.51±0.15, $p=6.9\times10^{-5}$ in FAMILY: Table 3), but not in the South Asian birth cohort (p=1410 411 0.41; Supplementary Table 8).

Among individuals who had never smoked, no statistically significant mean difference was observed in the distribution of the combined methylation score between South Asian and European cohorts (Supplementary Table 9). These results provided empirical support for the portability of an European-derived maternal smoking methylation score to South Asian populations.

418

419

420 Association between MRS and other phenotypes

421 The maternal smoking MRS was consistently associated with increasing weekly smoking 422 exposure in children reported by mothers at the 1-year visit (0.44 \pm 0.15, p= 0.0044) in CHILD, 423 and at 3-year visit (0.86 \pm 0.26, p = 0.0037; Supplementary Table 8) in FAMILY, but not in 424 START as everyone reported non-exposure to smoking. A higher maternal smoking MRS was significantly associated with lower birth weight (-0.05 \pm 0.01, p=3.4×10⁻⁴) and smaller birth size 425 $(-0.22\pm0.07, p=0.0016)$ in the combined European and South Asian cohorts (Table 3; 426 427 Supplementary Table 8). The meta-analysis revealed no heterogeneity in the direction nor the 428 effect size of associations for body size and weight between populations at birth or at later visits 429 (heterogeneity p-values = 0.18–1; Supplementary Table 8). The association between the MRS 430 and several children phenotypes, including height or length, weight, and skinfolds, appeared to 431 persist with similar estimated effects throughout early developmental years (Supplementary 432 Table 8), albeit the most significant effects were at birth, and the significance attenuated at later 433 visits. We did not find any association with self-reported allergy or asthma in children at later 434 visits (Supplementary Table 8). Further, there was no evidence of association between the MRS and any maternal outcomes (Supplementary Table 8). 435

436

437

438 **Discussion**

439

440 We examined the epigenetic signature of maternal smoking and smoking exposure using 441 newborn cord blood samples from predominately European-origin and South Asian cohorts via 442 two strategies: an individual CpG-level EWAS approach, and a multivariate approach in the 443 form of a methylation score. The EWAS results replicated the association between maternal 444 smoking and CpGs in the GFII gene that is well described in the literature with respect to 445 smoking (15,17), maternal smoking (19,20,56,57), and birth weight (23). In the latter case, we 446 observed a significant association with maternal smoking history and smoking exposure in 447 European-origin newborns. Further, we noted a weak dose-dependent relationship between 448 maternal smoking history and the methylation score in one European cohort (CHILD) but this 449 was not replicated in the other (FAMILY). Since the timing and duration of maternal smoking 450 during pregnancy were not directly available, these differences could play a role in the 451 magnitude and specificity of DNA methylation changes in cord blood. Finally, the significant 452 association of the MRS with the newborn health metrics in START, in the absence of mothers' 453 active smoking, could be the result of underreporting of smoking, poor recall of the time of 454 quitting, and/or due to air pollution exposure (58), leading to oxidative stress. This suggests that 455 our cord blood DNAm signature of maternal smoking is perhaps not unique to cigarette smoking, 456 but captures similar biochemical responses, for example, via the aryl hydrocarbon receptor 457 (59,60). Our observation that a higher MRS was associated with lower birth weight and smaller

458 birth length in both ethnic populations is thus consistent with the established link between 459 oxidative stress and metabolic syndrome (61).

460

461 Contrary to DNA methylation studies of smoking in adults, where whole blood is often 462 used as a proxy tissue, there are multiple relevant tissues for maternal smoking during pregnancy, 463 including the placenta of the mother, newborn cord blood, and children's whole blood. However, 464 methylation changes measured in whole blood or placenta of the mother, or cord blood of infants 465 showed substantially different patterns of association signals (62). There are several advantages 466 of using a cord blood based biomarker from the DoHaD perspective. Firstly, cord blood provides 467 a direct reflection of the *in utero* environment and fetal exposure to maternal smoking. 468 Additionally, since cord blood is collected at birth, it eliminates potential confounding factors 469 such as postnatal exposures that may affect maternal blood samples. Furthermore, studying cord 470 blood DNAm allows for the assessment of epigenetic changes specifically relevant to the 471 newborn, offering valuable information on the potential long-term health implications. 472 Meanwhile, methylation signals are known to be tissue-specific, thus it would be of interest for 473 future research to combine differential methylation patterns from all relevant tissue to assess the 474 immediate and long-term effects of maternal smoking. Another direction to further this line of 475 research is to explore postnatal factors that mitigate prenatal exposures, for example, 476 breastfeeding, which has been shown to have a protective effect against maternal tobacco 477 smoking (63). Indeed, more research is necessary to understand the critical periods of exposure 478 and the dose-response relationship between maternal smoking and cord blood DNA methylation 479 changes. Ongoing efforts to monitor the offspring and collect data in the next decade are in 480 progress to establish the long-term association between maternal smoking and cardio-metabolic

481 health (43,44). As such, the constructed MRS can facilitate future research in child health and482 will be included as part of the generated data for others to access.

483

484 The strengths of this report include ethnic diversity, and fine phenotyping in a 485 prospective and harmonized way with follow-up at multiple early childhood stages. This work is 486 the first major multi-ancestry study that utilizes methylation scores to study maternal smoking 487 and examines their portability from European-origin populations to South Asians. The use of 488 MRS, as compared to individual CpGs, is a powerful tool to systematically investigate the 489 influence of DNA methylation changes and whether it has lasting functional consequences on 490 health outcomes. Our results converge with previous findings that epigenetic associations of 491 maternal smoking are associated with newborn health, and add to the small body of evidence that 492 these relationships extend to non-European populations and that different ancestral populations 493 can experience the early developmental periods differently.

494

495 A few limitations should be mentioned. In the context of existing epigenetic studies of 496 maternal smoking, we were not able to replicate signals in other well-reported genes such as 497 AHRR, CYP1A1, and MYO1G, however, the MRS was able to pick up signals from these genes 498 (Supplementary Table 7). This could be due to several reasons. First, the customized array with a 499 limited number of CpGs (<3,000) was designed in 2016 and many large EWASs on smoking and 500 maternal smoking conducted more recently had not been included. Nonetheless, we have shown 501 that from a multivariate perspective, the MRS constructed using a targeted approach that was 502 carefully designed can be equally powerful with the advantage of being cost-effective. Second, 503 contrary to existing EWASs where the methylation values are typically treated as the outcome,

504 and the exposure, such as smoking, as the predictor; we reversed the regression such that the 505 methylation levels were the predictors and smoking exposure as the outcome. This reverse 506 regression approach is robust and our choice to reverse the regression was motivated by the goal 507 of constructing a smoking score that combines the additive effects at multiple CpGs, which 508 would otherwise be unfeasible. Third, systematic ancestral differences in DNA methylation 509 patterns had been shown to vary at individual CpGs in terms of their association with smoking 510 (30). Converging with this conclusion, we also found the association with GFI1 to be most 511 consistent after adjusting for cell composition. Finally, maternal smoking is often associated with 512 other confounding factors, such as socioeconomic status, other lifestyle behaviours, and 513 environmental exposures. While we have done our best to control for well-known confounders 514 that were available by study design, as in all observational studies, we could not account for 515 unknown confounding effects. Finally, in recent years, maternal smoking is on a decline as a 516 result of changes in social norms and public health policies (64). This is also consistent with the 517 lower smoking rates observed in our European cohorts (CHILD and FAMILY).

518

In conclusion, the epigenetic maternal smoking score we constructed was strongly associated with smoking status during pregnancy and self-reported smoking exposure in White Europeans, and with smaller birth size and lower birth weight in the combined South Asian and White European cohorts. The proposed cord blood epigenetic signature of maternal smoking has the potential to identify newborns who were exposed to maternal smoking *in utero* and to assess the long-term impact of smoking exposure on offspring health. In South Asian mothers with minimal smoking behaviour, the relationship between the methylation score and negative health

- 526 outcomes in newborns is still apparent, indicating that DNA methylation response is sensitive to
- 527 smoking exposure, even in the absence of active smoking.

- **Tables and Figure legends**
- 538 Table 1. Characteristics of the epigenetic subsample (1,267 mother–newborn pairs) from
- 539 the CHILD, FAMILY, START cohorts.

		CHILD	FAMILY	START	ANOVA F- test or Chi-
	Phenotypes	(N=352)	(N=411)	(N=504)	squared test P-value for differences
Mother	Smoking History				
	never smoked	247 (70.2%)	253 (61.6%)	501 (99.4%)	< 0.001*
	quit before this pregnancy quit during this	72 (20.5%)	58 (14.1%)	1 (0.2%)	
	pregnancy	17 (4.8%)	57 (13.9%)	1 (0.2%)	
	currently smoking	11 (3.1%)	29 (7.1%)	0 (0%)	
	Missing	5 (1.4%)	14 (3.4%)	1 (0.2%)	
	Smoking Exposure (hr/week)				
	Mean (SD)	0.97 (± 7.64)	2.52 (± 12.83)	0.33 (± 2.67)	< 0.001
	Missing Gestational Diabetes Mellitus	12 (3.4%)	5 (1.2%)	42 (8.3%)	

	YES	16 (4.5%)	66 (16.1%)	183 (36.3%)	< 0.001	
	NO	336 (95.5%)	345 (83.9%)	320 (63.5%)		
	Missing	0 (0%)	0 (0%)	1 (0.2%)		
	Years of Education				< 0.001	
	Mean (SD)	16.96 (± 3.08)	16.85 (± 3.39)	15.81 (± 2.41)		
	Missing	7 (2.0%)	3 (0.7%)	0 (0%)		
	Mother's Age					
	Mean (SD)	32.69 (± 4.45)	31.86 (± 5.42)	30.12 (± 3.91)	< 0.001	
	Missing	4 (1.1%)	0 (0%)	0 (0%)		
	Parity					
	Mean (SD)	$0.72 (\pm 0.88)$	0.80 (± 1.02)	$0.80 (\pm 0.81)$		0.0
	Missing	2 (0.6%)	0 (0%)	13 (2.6%)		
	Pre-pregnancy BMI (kg/m2)					
	(kg/m2) Mean (SD)	24.78 (± 5.42)	26.46 (± 6.38)	23.71 (± 4.45)	< 0.001	
	Missing	132 (37.5%)	16 (3.9%)	23.71 (± 4.43) 2 (0.4%)	<0.001	
	Newborn Sex	132 (37.370)	10 (3.9%)	2 (0.470)		
	Male	194 (55.1%)	211 (51.3%)	239 (47.4%)		0.0
	Female	158 (44.9%)	200 (48.7%)	265 (52.6%)		0.0
	Plant Based Diet	130 (44.970)	200 (40.770)	203 (32.070)		
	Mean (SD)	$-0.48 (\pm 0.46)$	0.19 (± 0.67)	1.56 (± 1.14)	< 0.001	
	Missing	23 (6.5%)	36 (8.8%)	16 (3.2%)	<0.001	
	Health Conscious Diet	23 (0.370)	50 (0.070)	10 (3.270)		
	Mean (SD)	0.21 (± 0.81)	-0.73 (± 0.73)	-0.42 (± 0.79)	< 0.001	
	Missing	23 (6.5%)	36 (8.8%)	16 (3.2%)	(0.001	
	Western Diet	20 (010 /0)		10 (0.270)		
	Mean (SD)	-0.15 (±0.63)	1.06 (± 1.20)	-0.51 (± 0.65)	< 0.001	
	Missing	23 (6.5%)	36 (8.8%)	16 (3.2%)		
Newborn	Gestational Age (weeks)		()			
	Mean (SD)	39.53 (± 1.38)	39.44 (± 1.47)	39.20 (± 1.32)	< 0.001	
	Missing	4 (1.1%)	0 (0%)	0 (0%)		
	Birth Length (cm)	× ,	~ /	~ /		
	Mean (SD)	51.68 (± 2.52)	50.20 (± 2.16)	51.44 (± 2.69)	< 0.001	
	Missing	71 (20.2%)	10 (2.4%)	7 (1.4%)		
	Birth Weight (kg)	× ,	× /	× /		
	Mean (SD)	3.50 (± 0.49)	3.53 (±0.50)	3.26 (± 0.46)	< 0.001	
	Missing	6 (1.7%)	0 (0%)	1 (0.2%)		
	Newborn BMI (kg/m2)	× /	~ /	× /		
	Mean (SD)	13.11 (± 1.41)	13.94 (± 1.29)	12.31 (± 1.39)	< 0.001	
	Missing	72 (20.5%)	10 (2.4%)	7 (1.4%)		
	Newborn Ponderal	· · · · · /				
	Index (kg/m3)					

	Mean (SD) Missing	25.45 (± 3.14) 72 (20.5%)	27.79 (± 2.55) 10 (2.4%)	24.02 (± 3.17) 7 (1.4%)	< 0.001
Estimated cell			10 (20070)	, (11.70)	
proportions	CD8T				
	Mean (SD)	0.01 (± 0.01)	$0.04 (\pm 0.03)$	$0.02 (\pm 0.02)$	< 0.001
	CD4T				
	Mean (SD)	0.11 (± 0.06)	0.13 (± 0.06)	$0.16 (\pm 0.07)$	< 0.001
	NK				
	Mean (SD)	$0.02 (\pm 0.02)$	$0.03 (\pm 0.03)$	$0.02 (\pm 0.03)$	< 0.001
	Bcell				
	Mean (SD)	$0.02 (\pm 0.02)$	$0.04 (\pm 0.03)$	$0.04 (\pm 0.03)$	< 0.001
	Mono				
	Mean (SD)	$0.01 (\pm 0.02)$	$0.04 (\pm 0.03)$	$0.03 (\pm 0.03)$	< 0.001
	Gran				
	Mean (SD)	$0.80 (\pm 0.10)$	$0.60 (\pm 0.13)$	$0.72 (\pm 0.14)$	< 0.001
	nRBC				
	Mean (SD)	$0.08~(\pm 0.08)$	$0.12 (\pm 0.11)$	$0.07 (\pm 0.11)$	< 0.001
	MNLR				
	Mean (SD)	6.59 (± 6.00)	3.30 (± 3.14)	3.98 (± 3.08)	< 0.001
	Missing	6 (1.7%)	0 (0%)	3 (0.6%)	

* comparison for CHILD and FAMILY only

540

542

- 543 Table 2. Meta-analysis results of association between CpGs and maternal smoking and smoking exposure that passed a
- 544 marginal p < 0.05 threshold after the false discovery rate correction in European cohorts.

				UCSC		Meta-an	alysis (CHIL	D and FAMILY)		t-specific on P-value	- Reported
	CHR	Position	СрG	Reference Gene	Fixed Effect	Standard Error	Assocition P-value	P-value for Effect Heterogeneity	FDR adjusted Association P-value	CHILD	FAMILY	Association EWAS catalog ^{alia}
Maternal Smoking	1	92481269	<u>cg12876356</u>	GF11	-1.11	0.22	7.33E-07	0.51	0.0019	0.02	9.45E-06	MS;S; AC; BW
~8	1	92482032	cg09935388	GF11	-1.15	0.24	2.26E-06	0.52	0.0029	0.02	2.71E-05	MS.GA. S. AR
	1	92482405	<u>cg14179389</u>	GFI1	-1.48	0.32	5.03E-06	0.73	0.0035	0.01	1.12E-04	MS;S
	1	92481144	<u>cg18146737</u>	GFI1	-0.92	0.20	5.58E-06	0.50	0.0035	0.04	3.95E-05	MS;S; AC; BY
	1	92480576	<u>cg09662411</u>	GFI1	-0.94	0.22	1.64E-05	0.29	0.0083	0.10	3.85E-05	MS;S
	1	92481479	cg18316974	GFI1	-0.74	0.18	3.58E-05	0.33	0.0152	0.13	7.34E-05	MS;S; AC; B
	17	2494783943	cg01798813	_	-0.83	0.21	1.09E-04	0.34	0.0395	0.02	0.0016	A; GA; BMI
Smoking Exposure	1	92482032	cg09935388	GF11	-0.18	0.04	1.39E-05	0.23	0.04	0.15	2.45E-05	A; GA; BMI CONTRACTOR OF CONTRACTON OF CONTRACTOR OF CONTRACTOR OF CONTRACTOR OF CONTRACTOR OF CONTA
_	17	2494783943	cg01798813	_	-0.18	0.04	3.30E-05	0.13	0.04	0.00035	0.013	A; GA; BMI

545

546 MS: maternal smoking

547 GA: gestational age

548	AC: alcohol consumption
549	BMI: body mass index
550	T2D: type 2 diabetes
551	A: age
552	BW: birth weight
553	
554	
555	
556	
557	
558	
559	
560	
561	
562	
563	

565 Table 3. Significant associations between maternal smoking methylation risk score and phenotypes in CHILD, FAMILY and

START.

		Meta-analys	sis (CHILD,]	Cohort-s	pecific association	on P-value		
	Fixed Effect	Standard Error	Assocition P-value	FDR adjusted Association P-value	P-value for Effect Heterogeneity	CHILD	FAMILY	START made av
Smoking Exposure (hr/week)	0.29	0.12	0.012	0.032	7.32E-07	5.40E-05	3.41E-05	0.58 e
Gestational Age (weeks)	0.30	0.12	0.011	0.032	1.70E-07	6.32E-05	6.38E-06	0.59 under
Birth Length (cm)	-0.22	0.07	0.0016	0.0076	0.33	0.35	0.16	0.0023
Birth Weight (kg)	-0.05	0.01	3.42E-04	0.0021	0.66	0.016	0.026	0.094
1-year Height (cm)	-0.38	0.09	2.00E-05	5.99E-04	0.89	0.047	0.0070	0.094 0.0079
1-year Weight (kg)	-0.09	0.04	0.018	0.044	1.00	0.16	0.17	0.19
2-year Height (cm)	-0.39	0.13	0.0018	0.0076	0.50	0.72	0.059	0.0067
3-year Skinfold thickness	0.52	0.14	1.08E-04	0.0015	0.24	0.014	0.0011	0.38
5-year Height (cm)	-0.43	0.17	0.0090	0.030	0.94	0.16	0.07	0.21
5-year Skinfold thickness	0.50	0.18	0.0061	0.023	0.59	0.019	0.089	0.77

568

569 Figure Legends:

570 Figure 1. Schematic overview of the analytical pipeline for the cord blood DNAm maternal

- 571 smoking score and association study.
- 572 * indicates cohort sample size including those with missing smoking history.

573

574 Figure 2. Manhattan plots of the meta-analyzed association between cord blood DNAm and
575 maternal smoking in Europeans.

576 Manhattan plots summarized the meta-analyzed association *p*-values between cord blood DNA 577 methylation levels and current maternal smoking (A) or smoking exposure (B) at a common set 578 of 2,114 CpG sites. The red line denotes the smallest -log10(*p*-value) that is below the FDR 579 correction threshold of 0.05. The red dots represent established associations with maternal 580 smoking reported in Joubert and colleagues (19).

581

Figure 3. Relationships between maternal smoking MRS and maternal smoking history
categories for each of the studies.

584

585 Maternal smoking methylation score (y-axis) was shown as a function of maternal smoking 586 history (x-axis) in levels of severity for prenatal exposure for each study. Each severity level was 587 compared to the never-smoking group and the corresponding two-sample *t*-test *p*-value was 588 reported. The analysis of variance via an F-test *p*-value was used to indicate whether a mean 589 difference in methylation score was present among all smoking history categories. The sample 590 size for START cohort was provided due to the low counts in categories of any smoking.

591	
592	Supporting Information captions
593	
594	Supplementary Material.
595	
596	Suppl. Table 1. Quality controls for the inclusion/exclusion of samples and methylation
597	probes.
598	
599	Suppl. Table 2. Characteristics of the overall sample include 5176 mother-newborn pairs
600	from the CHILD, FAMILY, and START cohorts.
601	
602	Suppl. Table 3. A summary of available analyses and outcome variables in each cohort.
603	
604	Suppl. Table 4. A summary of the DNAm maternal smoking score derivation design and
605	results.
606	
607	Suppl. Table 5. Score weights for external DNAm maternal smoking scores.
608	
609	Suppl. Table 6. Characteristics of the epigenetic subsample from CHILD and FAMILY
610	cohorts stratified by smoking status.
611	
612	Suppl. Table 7. A summary of CpGs that contribute to the DNAm maternal smoking scores
613	and their weights.

614

615	Suppl. Table 8. Association between maternal smoking methylation risk score and
616	phenotypes in CHILD, FAMILY and START.
617	Suppl. Table 9. Summary of mean difference in methylation risk scores between studies in
618	overall samples and those never smoked.
619	
620	
621	
622	
623	Supplementary Figure 1. Manhattan plots of the meta-analyzed association between cord
624	blood DNA methylation and ever maternal smoking in the combined European cohorts.
625	The meta-analyzed association <i>p</i> -values for ever maternal smoking and methylation levels at
626	2,114 CpG sites were summarized in the Manhattan plot. Ever maternal smoking was defined to
627	compare those who were currently smoking or quitted before or during this pregnancy vs. those
628	never smoked. The red line denotes the smallest $-\log 10(p-value)$ that is below the FDR
629	correction threshold of 0.05. The red dots represent established associations with maternal
630	smoking reported in Joubert and colleagues (19).
631	
632	Supplementary Figure 2. Quantile-quantile plots of the meta-analyzed association between
633	cord blood DNA methylation and maternal smoking history, smoking exposure in the
634	combined European cohorts.

Gas Quantile-quantile plots summarized the association *p*-values between cord blood DNA
methylation levels and current maternal smoking (A) or ever maternal smoking (B) or weekly

637	smoking exposure (C) at 2,114 CpG sites. The red line (y=x) is the line of reference and the
638	genomic inflation factor, calculated as the ratio between the observed median and the theoretical
639	median of the association test statistics, was annotated for each outcome.

640

Supplementary Figure 3. Scatterplots of meta-analyzed association effects for maternal smoking history or smoking exposure and reported effects of maternal smoking.

- 643 Panel A) is the scatterplot of meta-analyzed effects for maternal smoking in the combined
- 644 CHILD and FAMILY cohorts (x-axis) vs. reported effects for maternal smoking in Joubert et al.,
- 645 2016 (y-axis) for all CpGs present in CHILD, FAMILY, and Joubert et al., 2016 (# CpGs = 128);
- 646 Panel B) is the scatterplot of meta-analyzed effects for weekly smoking exposure in the
- 648 Joubert et al., 2016 (y-axis) for all CpGs present in CHILD, FAMILY, and Joubert et al., 2016 (#

combined CHILD and FAMILY cohorts (x-axis) vs. reported effects for maternal smoking in

- CpGs = 128). The solid gray line is the best fitted line (95% confidence interval shown as the shaded area) for the linear relationship between the effect sizes and the dashed gray line
- 651 represents the reference of y=x. (19)
- 652

647

653

Supplementary Figure 4. Manhattan plots of the Epigenome-wide associations between cord blood DNAm and maternal smoking history, smoking exposure in CHILD.

656 Manhattan plots summarized the association *p*-values between cord blood DNA methylation 657 levels and current maternal smoking (A) or ever maternal smoking (B) or weekly smoking 658 exposure (C) at 200,050 CpG sites. The red line denotes the smallest $-\log_{10}(p-value)$ that is

below the FDR correction threshold of 0.05. The red dots represent established associations withmaternal smoking reported in Joubert and colleagues (19).

661

662 (19)

Supplementary Figure 5. A comparison of results for derived and external maternal smoking MRSs.

665 Maternal smoking methylation score (y-axis) was shown as a function of maternal smoking 666 history (x-axis) in levels of severity ([0] = never smoked; [1] = quit before this pregnancy; [2] = 667 quit during this pregnancy; [3] = currently smoking) for prenatal exposure for each study. The 668 scores shown were validated in 1) CHILD, 2) CHILD but restricted to CpGs that were also 669 present on the targeted array, 3) FAMILY using CpGs on the targeted array. Each severity 670 level was compared to the never smoking group and the corresponding two sample *t*-test *p*-value 671 was reported. An omnibus test *p*-value to test whether a mean difference in methylation score 672 was present among all smoking history categories.

673

Supplementary Figure 6. A heatmap of correlation between derived and external maternal smoking MRSs.

This heatmap illustrates the pairwise correlation between MRSs calculated in A) CHILD, B) FAMILY, and C) START. Each cell represents the correlation coefficient, ranging from -1 to 1, indicating the strength and direction of the association. A value of 1 signifies a perfect positive correlation, while -1 indicates a perfect negative correlation. Values closer to 0 suggest no correlation. The color gradient from deep blue (strong negative correlation), through white (no

correlation), to deep red (strong positive correlation), visually encodes the strength of these
relationships. The scores in the black box were derived using lassosum and internally validated.

683

684 Supplementary Figure 7. Comparison of all methylation scores stratified by study.

The boxplots captured the standardized maternal smoking methylation scores (y-axis) stratified by study. The top panels summarized results for all samples in CHILD, FAMILY, and START, while the bottom panels summarized results for only those in CHILD, FAMILY, and START that never smoked. The *p*-values indicate the significance for a mean difference for each pairwise comparison between the HM450K score validated in CHILD with other scores using two-sample *t*-tests.

691

692

693 Acknowledgements

We express our sincere gratitude to all the participating families and the START, FAMILY, and CHILD study teams, including interviewers, nurses, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, and receptionists.

697

We would like to acknowledge the Genetic and Molecular Epidemiology Laboratory (GMEL), an associate of Hamilton Health Sciences and McMaster University, for their indispensable contributions to this work. The technical staff of GMEL conducted all epigenetic profiling, including sample processing and other technical operations.

702

We thank the members of the Nutrigen Alliance for providing the data: Sonia S. Anand;
Stephanie A. Atkinson; Meghan Azad; Allan B. Becker; Jeffrey Brook; Judah A Denburg;
Dipika Desai; Russell J. de Souza; Milan K. Gupta; Michael Kobor; Diana L. Lefebvre; Wendy
Lou; Piushkumar J. Mandhane; Sarah McDonald; Andrew Mente; David Meyre; Theo J. Moraes;
Katherine M. Morrison; Guillaume Paré; Malcolm R. Sears; Padmaja Subbarao; Koon K. Teo;
Stuart E. Turvey; Julie Wilson; Salim Yusuf; Gita Wahi; Michael A. Zulyniak.
This study was funded by the Canadian Institutes of Health Research Metabolomics Team Grant:

MWG-146332. Dr. Anand is supported by a Tier 1 Canada Research Chair in Ethnicity and CVD
and Heart, Stroke Foundation Chair in Population Health, a grant from the Canadian Partnership
Against Cancer, Heart and Stroke Foundation of Canada and Canadian Institutes of Health
Research. Dr. Azad is supported by a Tier 2 Canada Research Chair in the Developmental
Origins of Chronic Disease.

716 Data availability statement

The summary statistics used to construct methylation risk scores are available from EWAS catalog at <u>http://www.ewascatalog.org/?trait=maternal%20smoking%20in%20pregnancy</u> with additional filters of PubMID 27040690 and analysis on "Sustained maternal smoking in pregnancy effect on newborns adjusted for cell composition".

721

Summary statistics generated in the current study, including a total of 8 primary association studies (three smoking phenotypes in three cohorts) and 3 sets of meta-analyzed results in Europeans are available upon request. All scripts to reproduce and validate the predictive model

725	can	be	found	at
726	https://github.com/WeiAkane	Deng/EpigeneticResearch/tree	:/main/MaternalSmoking.	
727				
728	Conflicts of interest			
729	No conflict of interest.			
730				
731	Ethics Statement			
732	Ethical approval was obtain	ed independently from the H	Hamilton Integrated Research Ethi	CS
733	Board: CHILD (REB 07-292	29), FAMILY (REB 02–060),	and START (REB 10-640). CHIL	.D
734	was additionally approved l	by the respective Human Re	esearch Ethics Boards at McMast	ter
735	University, the Universities	of Manitoba, Alberta, and Br	itish Columbia, and the Hospital f	or
736	Sick Children. Legal guardia	ns of each participant provide	ed written informed consent. Writt	en
737	informed consent was obtain	ed from the parent/guardian	(participating mother) for each stud	dy
738	separately. We also have no	w obtained additional ethics	board approval from HiREB (RE	EB
739	16592) for using the data from	om the three cohorts together	without additional consent from t	he
740	participants.			

741 **Reference**

- Stock SJ, Bauld L. Maternal smoking and preterm birth: An unresolved health challenge.
 Vol. 17, PLoS Medicine. 2020.
- Liu B, Xu G, Sun Y, Qiu X, Ryckman KK, Yu Y, et al. Maternal cigarette smoking before
 and during pregnancy and the risk of preterm birth: A dose–response analysis of 25
 million mother–infant pairs. PLoS Med. 2020;17(8).
- Marufu TC, Ahankari A, Coleman T, Lewis S. Maternal smoking and the risk of still birth:
 systematic review and meta-analysis. BMC Public Health. 2015;15(1).
- Ventura SJ, Hamilton BE, Mathews TJ, Chandra A. Trends and variations in smoking
 during pregnancy and low birth weight: Evidence from the birth certificate, 1990-2000.
 Pediatrics. 2003;111(5 II).

U.S. Department of Health and Human Services. The Health Consequences of Smoking-

753

5.

754 50 Years of Progress A Report of the Surgeon General. A Report of the Surgeon General. 755 2014. 756 6. Montgomery SM, Ekbom A. Smoking during pregnancy and diabetes mellitus in a British 757 longitudinal birth cohort. Br Med J. 2002;324(7328). 758 Toschke A, Koletzko B, Slikker W, Hermann M, von Kries R. Childhood obesity is 7. 759 associated with maternal smoking in pregnancy. Eur J Pediatr. 2002;161(8). 760 8. Oken E, Levitan EB, Gillman MW. Maternal smoking during pregnancy and child 761 overweight: Systematic review and meta-analysis. Vol. 32, International Journal of 762 Obesity. 2008. 763 9. Philips EM, Santos S, Trasande L, Aurrekoetxea JJ, Barros H, von Berg A, et al. Changes 764 in parental smoking during pregnancy and risks of adverse birth outcomes and childhood 765 overweight in Europe and North America: An individual participant data meta-analysis of 766 229,000 singleton births. PLoS Med. 2020;17(8). 767 10. England LJ, Grauman A, Qian C, Wilkins DG, Schisterman EF, Yu KF, et al. 768 Misclassification of maternal smoking status and its effects on an epidemiologic study of 769 pregnancy outcomes. Nicotine and Tobacco Research. 2007;9(10). 770 11. Shipton D, Tappin DM, Vadiveloo T, Crossley JA, Aitken DA, Chalmers J. Reliability of 771 self reported smoking status by pregnant women for estimating smoking prevalence: A 772 retrospective, cross sectional study. BMJ (Online). 2009;339(7732). 773 12. Salmasi G, Grady R, Jones J, McDonald SD. Environmental tobacco smoke exposure and 774 perinatal outcomes: a systematic review and meta-analyses. Vol. 89, Acta obstetricia et 775 gynecologica Scandinavica. 2010. 776 13. Yousefi PD, Suderman M, Langdon R, Whitehurst O, Davey Smith G, Relton CL. DNA 777 methylation-based predictors of health: applications and statistical considerations. Vol. 23, 778 Nature Reviews Genetics. 2022. 779 14. Shenker NS, Ueland PM, Polidoro S, Van Veldhoven K, Ricceri F, Brown R, et al. DNA 780 methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology. 781 2013;24(5).782 15. Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR, et al. 783 Epigenetic Signatures of Cigarette Smoking. Circ Cardiovasc Genet. 2016;9(5). 784 16. Guida F, Sandanger TM, Castagné R, Campanella G, Polidoro S, Palli D, et al. Dynamics of smoking-induced genome-wide methylation changes with time since smoking cessation. 785 786 Hum Mol Genet. 2015;24(8). 787 17. Sikdar S, Joehanes R, Joubert BR, Xu CJ, Vives-Usano M, Rezwan FI, et al. Comparison 788 of smoking-related DNA methylation between newborns from prenatal exposure and 789 adults from personal smoking. Epigenomics. 2019;11(13). 790 18. Zeilinger S, Kühnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco 791 Smoking Leads to Extensive Genome-Wide Changes in DNA Methylation. PLoS One. 792 2013 May 17;8(5). 793 19. Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, et al. DNA 794 Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide 795 Consortium Meta-analysis. Am J Hum Genet. 2016;98(4). 796 20. Hannon E, Schendel D, Ladd-Acosta C, Grove J, Hansen CS, Hougaard DM, et al. 797 Variable DNA methylation in neonates mediates the association between prenatal

smoking and birth weight. Philosophical Transactions of the Royal Society B: Biological


798

799 Sciences. 2019;374(1770). 800 21. Akhabir L, Stringer R, Desai D, Mandhane PJ, Azad MB, Moraes TJ, et al. DNA 801 methylation changes in cord blood and the developmental origins of health and disease – a 802 systematic review and replication study. BMC Genomics. 2022;23(1). 22. 803 Witt SH, Frank J, Gilles M, Lang M, Treutlein J, Streit F, et al. Impact on birth weight of 804 maternal smoking throughout pregnancy mediated by DNA methylation. BMC Genomics. 805 2018;19(1). 806 23. Küpers LK, Xu X, Jankipersadsing SA, Vaez A, La Bastide-van Gemert S, Scholtens S, et 807 al. DNA methylation mediates the effect of maternal smoking during pregnancy on 808 birthweight of the offspring. Int J Epidemiol. 2015;44(4). 809 24. Xu R, Hong X, Zhang B, Huang W, Hou W, Wang G, et al. DNA methylation mediates 810 the effect of maternal smoking on offspring birthweight: a birth cohort study of multi-811 ethnic US mother-newborn pairs. Clin Epigenetics. 2021;13(1). 812 25. Cardenas A, Lutz SM, Everson TM, Perron P, Bouchard L, Hivert MF. Mediation by 813 Placental DNA Methylation of the Association of Prenatal Maternal Smoking and Birth 814 Weight. Am J Epidemiol. 2019;188(11). 815 26. Murray R, Kitaba N, Antoun E, Titcombe P, Barton S, Cooper C, et al. Influence of 816 maternal lifestyle and diet on perinatal DNA methylation signatures associated with 817 childhood arterial stiffness at 8 to 9 years. Hypertension. 2021;78(3). 818 Raynor P, Duley L, Small N, Tuffnell D, Wild C, Wright J, et al. Born in Bradford, a 27. 819 cohort study of babies born in Bradford, and their parents: Protocol for the recruitment 820 phase. BMC Public Health. 2008;8. 821 28. Elliott HR, Burrows K, Min JL, Tillin T, Mason D, Wright J, et al. Characterisation of 822 ethnic differences in DNA methylation between UK-resident South Asians and Europeans. 823 Clin Epigenetics [Internet]. 2022 Dec 1 [cited 2023 Mar 9];14(1). Available from: 824 https://pubmed.ncbi.nlm.nih.gov/36243740/ 825 29. Choquet H, Yin J, Jorgenson E. Cigarette smoking behaviors and the importance of 826 ethnicity and genetic ancestry. Transl Psychiatry. 2021;11(1). 827 30. Elliott HR, Tillin T, McArdle WL, Ho K, Duggirala A, Frayling TM, et al. Differences in 828 smoking associated DNA methylation patterns in South Asians and Europeans. Clin 829 Epigenetics. 2014;6(1). 830 Bollepalli S, Korhonen T, Kaprio J, Anders S, Ollikainen M. EpiSmokEr: A robust 31. 831 classifier to determine smoking status from DNA methylation data. Epigenomics. 832 2019;11(13). 833 32. Wright J, Small N, Raynor P, Tuffnell D, Bhopal R, Cameron N, et al. Cohort profile: The 834 born in bradford multi-ethnic family cohort study. Int J Epidemiol. 2013;42(4). 835 33. Reitsma MB, Flor LS, Mullany EC, Gupta V, Hay SI, Gakidou E. Spatial, temporal, and 836 demographic patterns in prevalence of smoking tobacco use and initiation among young 837 people in 204 countries and territories, 1990–2019. Lancet Public Health. 2021;6(7). 838 34. de Souza RJ, Zulyniak MA, Desai D, Shaikh MR, Campbell NC, Lefebvre DL, et al. 839 Harmonization of food-frequency questionnaires and dietary pattern analysis in 4 840 ethnically diverse birth cohorts. Journal of Nutrition. 2016;146(11). 841 35. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA 842 methylation array with single CpG site resolution. Genomics. 2011;98(4).


843 36. Zhou W, Triche TJ, Laird PW, Shen H. SeSAMe: Reducing artifactual detection of DNA 844 methylation by Infinium BeadChips in genomic deletions. Nucleic Acids Res. 845 2018;46(20). 846 37. Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et al. 847 Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium 848 HumanMethylation450 microarray. Epigenetics. 2013;8(2). 849 38. Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative 850 use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res. 2017;45(4). 851 39. Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, et al. Critical 852 evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome 853 DNA methylation profiling. Genome Biol. 2016;17(1). 854 40. Hillary RF, McCartney DL, McRae AF, Campbell A, Walker RM, Hayward C, et al. 855 Identification of influential probe types in epigenetic predictions of human traits: 856 implications for microarray design. Clin Epigenetics. 2022;14(1). 857 41. Gervin K, Salas LA, Bakulski KM, Van Zelm MC, Koestler DC, Wiencke JK, et al. 858 Systematic evaluation and validation of reference and library selection methods for 859 deconvolution of cord blood DNA methylation data. Clin Epigenetics. 2019;11(1). 860 42. R Core Team. R core team (2021). R: A language and environment for statistical 861 computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www. R-862 project. org. 2021. 43. Morrison KM, Atkinson SA, Yusuf S, Bourgeois J, McDonald S, McQueen MJ, et al. The 863 864 Family Atherosclerosis Monitoring In earLY life (FAMILY) study. Rationale, design, and 865 baseline data of a study examining the early determinants of atherosclerosis. Am Heart J. 866 2009;158(4). 867 44. Anand SS, Vasudevan A, Gupta M, Morrison K, Kurpad A, Teo KK, et al. Rationale and 868 design of South Asian Birth Cohort (START): A Canada-India collaborative study. BMC 869 Public Health. 2013;13(1). 870 45. Metzger BE. International Association of Diabetes and Pregnancy Study Groups 871 recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Vol. 872 33, Diabetes Care. 2010. 873 Anand SS, Razak F, Davis AD, Jacobs R, Vuksan V, Teo K, et al. Social disadvantage 46. 874 and cardiovascular disease: Development of an index and analysis of age, sex, and 875 ethnicity effects. Int J Epidemiol. 2006;35(5). 876 47. Mak TSH, Porsch RM, Choi SW, Zhou X, Sham PC. Polygenic scores via penalized 877 regression on summary statistics. Genet Epidemiol. 2017;(February):469-80. 878 Reese SE, Zhao S, Wu MC, Joubert BR, Parr CL, Håberg SE, et al. DNA methylation 48. 879 score as a biomarker in newborns for sustained maternal smoking during pregnancy. 880 Environ Health Perspect. 2017;125(4). 881 49. Richmond RC, Suderman M, Langdon R, Relton CL, Smith GD. DNA methylation as a 882 marker for prenatal smoke exposure in adults. Int J Epidemiol [Internet]. 2018 Aug 1 883 [cited 2023 Mar 9];47(4):1120–30. Available from: 884 https://academic.oup.com/ije/article/47/4/1120/5026413 885 Rauschert S, Melton PE, Burdge G, Craig J, Godfrey KM, Holbrook JD, et al. Maternal 50. 886 smoking during pregnancy induces persistent epigenetic changes into adolescence, 887 independent of postnatal smoke exposure and is associated with cardiometabolic risk. 888 Front Genet. 2019;10(JUL).


- Sondalia R, Baldassari A, Holliday KM, Justice AE, Méndez-Giráldez R, Stewart JD, et
 al. Methylome-wide association study provides evidence of particulate matter air
 pollution-associated DNA methylation. Environ Int. 2019;132.
- Subbarao P, Anand SS, Becker AB, Befus AD, Brauer M, Brook JR, et al. The Canadian
 Healthy Infant Longitudinal Development (CHILD) study: Examining developmental
 origins of allergy and asthma. Thorax. 2015;70(10).
- 895 53. Brydon P, Smith T, Proffitt M, Gee H, Holder R, Dunne F. Pregnancy outcome in women
 896 with type 2 diabetes mellitus needs to be addressed. Int J Clin Pract. 2000;54(7).
- 54. Farrar D, Fairley L, Santorelli G, Tuffnell D, Sheldon TA, Wright J, et al. Association
 between hyperglycaemia and adverse perinatal outcomes in south Asian and white British
 women: analysis of data from the Born in Bradford cohort. Lancet Diabetes Endocrinol
 [Internet]. 2015 Oct 1 [cited 2023 Jun 8];3(10):795. Available from:
 /pmc/articles/PMC4673084/
- 55. Lange S, Probst C, Rehm J, Popova S. National, regional, and global prevalence of
 smoking during pregnancy in the general population: a systematic review and metaanalysis. Lancet Glob Health. 2018;6(7).
- 56. Markunas CA, Xu Z, Harlid S, Wade PA, Lie RT, Taylor JA, et al. Identification of DNA
 Methylation Changes in Newborns Related to Maternal Smoking during Pregnancy.
 Environ Health Perspect. 2014;122(10).
- 908 57. Richmond RC, Simpkin AJ, Woodward G, Gaunt TR, Lyttleton O, McArdle WL, et al.
 909 Prenatal exposure to maternal smoking and offspring DNA methylation across the
 910 lifecourse: Findings from the Avon Longitudinal Study of Parents and Children
 911 (ALSPAC). Hum Mol Genet. 2015;24(8).
- 8. Rider CF, Carlsten C. Air pollution and DNA methylation: Effects of exposure in humans.
 Vol. 11, Clinical Epigenetics. 2019.
- 59. Vogel CFA, Van Winkle LS, Esser C, Haarmann-Stemmann T. The aryl hydrocarbon
 receptor as a target of environmental stressors Implications for pollution mediated stress
 and inflammatory responses. Vol. 34, Redox Biology. 2020.
- 80. Reynolds LM, Wan M, Ding J, Taylor JR, Lohman K, Su D, et al. DNA Methylation of
 81. the Aryl Hydrocarbon Receptor Repressor Associations with Cigarette Smoking and
 81. Subclinical Atherosclerosis. Circ Cardiovasc Genet. 2015;8(5).
- 920 61. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Vol. 84, Life Sciences.
 921 2009.
- 62. Everson TM, Vives-Usano M, Seyve E, Cardenas A, Lacasaña M, Craig JM, et al.
 Placental DNA methylation signatures of maternal smoking during pregnancy and
 potential impacts on fetal growth. Nat Commun. 2021;12(1).
- 63. Moshammer H, Hutter HP. Breast-feeding protects children from adverse effects of
 environmental Tobacco smoke. Int J Environ Res Public Health. 2019;16(3).
- Martin JA, Osterman MJK, Driscoll AK. Declines in Cigarette Smoking During
 Pregnancy in the United States, 2016-2021. NCHS Data Brief. 2023;(458).
- 929 930
- 931

A) Construction of MRS using lassosum



C) DNAm scores association with health outcomes






Chromosome

Chromosome

chrX

S



Maternal Smoking History